Other: Natalizumab ( DrugBank: Natalizumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02775110 (ClinicalTrials.gov)	November 2012	29/12/2015	Natalizumab Temporary Discontinuation Study	Natalizumab Temporary Discontinuation Study	Multiple Sclerosis	Other: Natalizumab discontinuation	University at Buffalo	NULL	Completed	18 Years	65 Years	Both	50	Phase 4	United States
2	NCT01065727 (ClinicalTrials.gov)	February 2010	8/2/2010	Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis	Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis	Multiple Sclerosis	Other: mitoxantrone - immunomodulator;Other: natalizumab	Rennes University Hospital	NULL	Recruiting	18 Years	N/A	Both	250	N/A	France
3	NCT00884481 (ClinicalTrials.gov)	March 23, 2009	17/4/2009	Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS	A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months	Relapsing-Remitting Multiple Sclerosis;Fatigue	Other: Natalizumab	Biogen	NULL	Completed	18 Years	65 Years	All	195		Austria;Denmark;Norway;Sweden;United States